Results 141 to 150 of about 829,320 (360)

Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society [PDF]

, 2009
Background: No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices.
Boeck, Stefan, Bruns, Christiane J., Heinemann, Volker, Jauch, Karl-Walter, Sargent, Mirja, Schäfer, Claus, Seufferlein, Thomas   +6 more
core   +1 more source

Targeting Splenic Myeloid Cells with Nanobiologics to Prevent Postablative Pancreatic Cancer Recurrence via Inducing Antitumor Peripheral Trained Immunity

Advanced Science, EarlyView.
Using a preclinical pancreatic cancer model, we identified that tumor progression restructures splenic immunity via myeloid cell expansion. MDCa@RBC‐Alipo nanobiologics were engineered to epigenetically and metabolically reprogram splenic myeloid cells, alleviating post‐ablation immunosuppression.
Shengbo Wu, Weichen Xu, Xuexia Shan, Liping Sun, Shuo Liu, Xixi Sun, Shaoyue Li, Xiaodong Hou, Xiaowan Bo, Chengzhong Peng, Bin Huang, Huixiong Xu, Wenwen Yue   +12 more
wiley   +1 more source

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis

Journal of Global Oncology, 2018
Purpose: The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain.
Renata Rodrigues da Cunha Colombo Bonadio, Renata Gondim Meira Velame Azevedo, Guilherme Harada, Samantha Cabral Severino da Costa, Vanessa Costa Miranda, Daniela de Freitas, Elias Abdo Filho, Patricia Alves de Oliveira Ferreira, Flavia Gabrielli, Maria Del Pilar Estevez Diz   +9 more
doaj   +1 more source

A current perspective on stereotactic body radiation therapy for pancreatic cancer. [PDF]

, 2016
Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option.
Czito, Brian G, Hong, Julian C, Palta, Manisha, Willett, Christopher G   +3 more
core   +2 more sources

Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma

Scientific Reports, 2016
There is relatively little literature on adjuvant radiotherapy after radical nephroureterectomy with bladder cuff excision (RNU) for patients with upper tract urothelial carcinoma (UTUC).
Yun-Ching Huang, Ying-Hsu Chang, Kuo-Hsiung Chiu, A. Shindel, Chia-Hsuan Lai   +4 more
semanticscholar   +1 more source

BAG2 Inhibits Cervical Cancer Progression by Modulating Type I Interferon Signaling through Stabilizing STING

Advanced Science, EarlyView.
Based on IP‐MS analysis, BAG2 is confirmed to be essential for ubiquitination and protein homeostasis regulation of STING in cervical cancer. BAG2 inhibits the ubiquitination and degradation of STING by forming a complex with STUB1, thereby activating the type I IFN signaling pathway and inhibiting the development of cervical cancer.
Shijie Yao, Siming Chen, Anjin Wang, Ziyan Liang, Xuelian Liu, Yang Gao, Hongbing Cai   +6 more
wiley   +1 more source

Track structure modelling for ion radiotherapy [PDF]

arXiv, 2014
In its broadest terms, doctoral dissertation entitled "Track structure modelling for ion radiotherapy" is part of the supporting research background in the development of the ambitious proton radiotherapy project currently under way at the Institute of Nuclear Physics PAN in Krak\'ow.
arxiv  

Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973-2004): the potential role of health care. [PDF]

, 2011
BACKGROUND: Socioeconomic inequalities in cancer survival are well documented but they vary for different cancers and over time. Reasons for these differences are poorly understood.
Barbiere, JM, Baum, M, Coleman, MP, Lyratzopoulos, G, Rachet, B, Thompson, MR   +5 more
core   +1 more source

Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.

Annals of Oncology, 2015
BACKGROUND The discussion on the role of adjuvant chemotherapy for rectal cancer patients treated according to current guidelines is still ongoing. A multicentre, randomized phase III trial, PROCTOR-SCRIPT, was conducted to compare adjuvant chemotherapy ...
A. Breugom, W. Gijn, E. Muller, A. Berglund, C. V. D. Broek, T. Fokstuen, H. Gelderblom, E. Kapiteijn, J. Leer, C. Marijnen, H. Martijn, E. Kranenbarg, I. Nagtegaal, L. Påhlman, C. Punt, H. Putter, A. Roodvoets, H. Rutten, W. Steup, B. Glimelius, B. Glimelius, C. Velde   +21 more
semanticscholar   +1 more source

Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer

Advanced Science, EarlyView.
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng, Yunfang Yu, Wenjun Qiu, Qiyun Ou, Qianqian Mao, Luyang Jiang, Jianhua Wu, Jiani Wu, Huiyan Luo, Peng Luo, Wenchao Gu, Na Huang, Siting Zheng, Shaowei Li, Yonghong Lai, Xiatong Huang, Yiran Fang, Qiongzhi Zhao, Rui Zhou, Huiying Sun, Wei Zhang, Jianping Bin, Yulin Liao, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Min Shi, Wangjun Liao   +27 more
wiley   +1 more source